Kemik Kaybı ve Osteoporoz
Özet
Kemik metastazları; özellikle akciğer, meme ve prostat kanserleri gibi solid tümörlerde sık görülen bir uzak nüks bulgusudur. Kanserin kemik metastazları yoluyla yayılması, hastalarda iskeletle ilişkili olaylara (SRE'ler) neden olarak ciddi morbiditeye yol açabilir. Bu olaylar arasında patolojik kırıklar, hiperkalsemi ve spinal kord kompresyonu yer almaktadır.Kemik metastazlarının gelişim mekanizmaları tam olarak aydınlatılamamış olsa da, osteoklast ve osteoblast aktivitesinin dengesizliği önemli bir rol oynar. Kanser hücreleri kemikte tutunduktan sonra, osteoklastları aktive ederek kemik yıkımına neden olur ve malign hücrelerin çoğalmasını teşvik eden bir döngü oluşturur.Meme ve prostat kanserli hastaların büyük bir kısmında otopsi sırasında kemik metastazları saptanmıştır. Metastatik kemik lezyonları genellikle asemptomatik olabilir, ancak en yaygın belirti ağrıdır. Ağrının şiddeti, kemik metastazının türüne ve yerine bağlı olarak değişebilir. Omurga metastazları, spinal instabilite veya omurilik basısı nedeniyle nörolojik defisitlere yol açabilir.Kemik metastazlarının tespitinde görüntüleme yöntemleri kritik öneme sahiptir. MRG, metastazın kemik iliği infiltrasyonunu belirlemede en hassas yöntemdir. BT, kemik bütünlüğünü değerlendirmede faydalı olup, PET/BT ise metastazların yayılımını saptamada etkilidir. Osteolitik metastazlar için kemik sintigrafisinin duyarlılığı düşük olup, multipl miyelom hastalarında daha az tercih edilir.Kemik metastazlarının tedavisinde osteoklast inhibitörleri (bisfosfonatlar ve denosumab) önemli bir yer tutmaktadır. Bu ajanlar, SRE’lerin sıklığını azaltarak hastaların yaşam kalitesini artırmaktadır. Zoledronik asit ve denosumab, kemik metastazlarıyla ilişkili olayları önleme açısından benzer etkilere sahiptir. Tedavi süresi konusunda kesin bir protokol bulunmamakla birlikte, hastanın klinik durumuna göre 2 yıl sonunda tedaviye ara verme veya seyrek dozlama yaklaşımları değerlendirilmektedir.Sonuç olarak, kemik metastazları kanser hastalarında önemli bir sağlık sorunudur ve erken tanı ile etkin yönetim, hasta prognozu üzerinde olumlu etkiler sağlayabilir.
Bone metastases are a common distant recurrence feature, especially in solid tumors such as lung, breast, and prostate cancers. The spread of cancer through bone metastases can lead to skeletal-related events (SREs), causing significant morbidity. These events include pathological fractures, hypercalcemia, and spinal cord compression.Although the exact mechanisms of bone metastases are not fully understood, the imbalance between osteoclast and osteoblast activity plays a crucial role. Once cancer cells settle in the bone, they activate osteoclasts, leading to bone resorption and creating a vicious cycle that promotes the proliferation of malignant cells.A significant proportion of patients with breast and prostate cancer have bone metastases detected during autopsy. Metastatic bone lesions are often asymptomatic, but pain is the most common symptom. The severity of pain depends on the type and location of bone metastases. Spinal metastases can lead to neurological deficits due to spinal instability or spinal cord compression.Imaging techniques play a critical role in detecting bone metastases. MRI is the most sensitive method for identifying bone marrow infiltration by metastases. CT is useful for assessing bone integrity, while PET/CT is effective in detecting the spread of metastases. Bone scintigraphy has low sensitivity for osteolytic metastases and is less preferred in patients with multiple myeloma.Osteoclast inhibitors (bisphosphonates and denosumab) play a significant role in the treatment of bone metastases. These agents help reduce the frequency of SREs, improving patients' quality of life. Zoledronic acid and denosumab have similar efficacy in preventing bone-related events. Although there is no definitive protocol regarding the duration of treatment, approaches such as treatment discontinuation after two years or extended dosing intervals are considered based on the patient’s clinical condition.In conclusion, bone metastases pose a significant health burden in cancer patients, and early diagnosis combined with effective management can positively impact patient prognosis.
Referanslar
Mundy, G.R., Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer, 2002. 2(8): p. 584-593.
Coleman, R.E., Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical cancer research, 2006. 12(20): p. 6243s-6249s.
Pockett, R., et al., The hospital burden of disease associated with bone metastases and skeletal‐related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. European journal of cancer care, 2010. 19(6): p. 755-760.
Theriault, R.L. and R.L. Theriault, Biology of bone metastases. Cancer Control, 2012. 19(2): p. 92-101.
Nielsen, O.S., Palliative radiotherapy of bone metastases: there is now evidence for the use of single fractions. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 1999. 52(2): p. 95-96.
Eastley, N., M. Newey, and R.U. Ashford, Skeletal metastases–the role of the orthopaedic and spinal surgeon. Surgical oncology, 2012. 21(3): p. 216-222.
Bubendorf, L., et al., Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human pathology, 2000. 31(5): p. 578-583.
Lee, Y.T.N., Breast carcinoma: pattern of metastasis at autopsy. Journal of surgical oncology, 1983. 23(3): p. 175-180.
Dispenzieri, A., POEMS syndrome: 2014 update on diagnosis, risk‐stratification, and management. American journal of hematology, 2014. 89(2): p. 213-223.
Chia, S.K., et al., The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer. Cancer, 2007. 110(5): p. 973-979.
Ryan, C.J., et al., Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer, 2007. 110(1): p. 81-86.
Walker, M.S., et al., Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases. Journal of medical economics, 2013. 16(1): p. 179-189.
Brodowicz, T., K. O'Byrne, and C. Manegold, Bone matters in lung cancer. Annals of oncology, 2012. 23(9): p. 2215-2222.
Schulman, K.L. and J. Kohles, Economic burden of metastatic bone disease in the US. Cancer, 2007. 109(11): p. 2334-2342.
Svendsen, M.L., et al., Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark. Clinical Epidemiology, 2013: p. 97-103.
McDonald, R., et al., Classification of painful bone metastases as mild, moderate, or severe using both EORTC QLQ-C15-PAL and EORTC QLQ-BM22. Supportive Care in Cancer, 2016. 24: p. 4871-4878.
Miric, A., et al., Cortical metastatic lesions of the appendicular skeleton from tumors of known primary origin. Journal of surgical oncology, 1998. 67(4): p. 255-260.
Greenspan, A. and A. Norman, Osteolytic cortical destruction: an unusual pattern of skeletal metastases. Skeletal radiology, 1988. 17: p. 402-406.
Choi, J. and M. Raghavan, Diagnostic imaging and image-guided therapy of skeletal metastases. Cancer Control, 2012. 19(2): p. 102-112.
Krishnamurthy, G.T., et al., Distribution pattern of metastatic bone disease: a need for total body skeletal image. Jama, 1977. 237(23): p. 2504-2506.
Tubiana-Hulin, M., Incidence, prevalence and distribution of bone metastases. Bone, 1991. 12: p. S9-S10.
Borgohain, B., et al., Occult renal cell carcinoma with acrometastasis and ipsilateral juxta-articular knee lesions mimicking acute inflammation. Advanced Biomedical Research, 2012. 1(1): p. 48.
Koyama, M. and M. Koizumi, FDG-PET images of acrometastases. Clinical Nuclear Medicine, 2014. 39(3): p. 298-300.
oncology., N.C.C.N.N.N.c.p.g.i., NCCN, 2024.
Muindi, J., et al., The role of computed tomography in the detection of bone metastases in breast cancer patients. The British Journal of Radiology, 1983. 56(664): p. 233-236.
Galasko, C.S., The value of scintigraphy in malignant disease. Cancer Treatment Reviews, 1975. 2(4): p. 225-272.
Hamaoka, T., et al., Bone imaging in metastatic breast cancer. Journal of Clinical Oncology, 2004. 22(14): p. 2942-2953.
Perez, D., et al., Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy. The Lancet, 1983. 322(8350): p. 613-616.
Even-Sapir, E., Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. Journal of Nuclear Medicine, 2005. 46(8): p. 1356-1367.
Bickels, J., S. Dadia, and Z. Lidar, Surgical management of metastatic bone disease. JBJS, 2009. 91(6): p. 1503-1516.
Metastatic bone disease. American College of Radiology Appropriateness Criteria, July 10, 2018.
Rybak, L. and D. Rosenthal, Radiological imaging for the diagnosis of bone metastases. QJ Nucl Med, 2001. 45(1): p. 53-64.
Mahnken, A., et al., Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. American journal of roentgenology, 2002. 178(6): p. 1429-1436.
Yang, H.-L., et al., Diagnosis of bone metastases: a meta-analysis comparing 18 FDG PET, CT, MRI and bone scintigraphy. European radiology, 2011. 21: p. 2604-2617.
Frank, J., et al., Detection of malignant bone tumors: MR imaging vs scintigraphy. AJR. American journal of roentgenology, 1990. 155(5): p. 1043-1048.
Antoch, G., et al., Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. Jama, 2003. 290(24): p. 3199-3206.
Steinborn, M.M., et al., Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. Journal of computer assisted tomography, 1999. 23(1): p. 123-129.
Haubold-Reuter, B., et al., The value of bone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumours: a prospective study. European journal of nuclear medicine, 1993. 20: p. 1063-1069.
Daldrup-Link, H.E., et al., Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. American Journal of Roentgenology, 2001. 177(1): p. 229-236.
Godersky, J.C., W.R. Smoker, and R. Knutzon, Use of magnetic resonance imaging in the evaluation of metastatic spinal disease. Neurosurgery, 1987. 21(5): p. 676-680.
Baur-Melnyk, A., et al., Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. American Journal of Roentgenology, 2008. 190(4): p. 1097-1104.
Liu, T., et al., Detection of vertebral metastases: a meta-analysis comparing MRI, CT, PET, BS and BS with SPECT. Journal of cancer research and clinical oncology, 2017. 143: p. 457-465.
Dimopoulos, M.A., et al., Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. Journal of Clinical Oncology, 2015. 33(6): p. 657-664.
Qu, X., et al., A meta-analysis of 18FDG-PET–CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. European journal of radiology, 2012. 81(5): p. 1007-1015.
Shen, G., et al., Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal radiology, 2014. 43: p. 1503-1513.
Savelli, G., et al., Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. QJ Nucl Med, 2001. 45(1): p. 27-37.
Bombardieri, E., et al., The role bone SPET study in diagnosis of single vertebral metastases. THE JOURNAL OF NUCLEAR MEDICINE, 2000. 41(5): p. 291P-291P.
Ryan, P.J. and I. Fogelman. The bone scan: where are we now? in Seminars in Nuclear Medicine. 1995. Elsevier.
Roland, J., et al., Metastases seen on SPECT imaging despite a normal planar bone scan. Clinical nuclear medicine, 1995. 20(12): p. 1052-1054.
Sedonja, I. and N.V. BUDIHNA, The benefit of SPECT when added to planar scintigraphy in patients with bone metastases in the spine. Clinical nuclear medicine, 1999. 24(6): p. 407-413.
Völker, T., et al., Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. Journal of Clinical Oncology, 2007. 25(34): p. 5435-5441.
Peterson, J.J. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors. in Seminars in musculoskeletal radiology. 2007. © Thieme Medical Publishers.
Staudenherz, A., et al., Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma? Cancer: Interdisciplinary International Journal of the American Cancer Society, 1999. 85(1): p. 153-155.
Brown, D.H. and M. Leakos, The value of a routine bone scan in a metastatic survey. Journal of Otolaryngology-Head & Neck Surgery, 1998. 27(4): p. 187.
Sanli, Y., et al., Neuroendocrine tumor diagnosis and management: 68Ga-DOTATATE PET/CT. American Journal of Roentgenology, 2018. 211(2): p. 267-277.
Ng, T.L., et al., Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Supportive Care in Cancer, 2021. 29: p. 925-943.
Wang-Gillam, A., D.A. Miles, and L.F. Hutchins, Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates. The oncologist, 2008. 13(7): p. 821-827.
Body, J.-J., et al., Hypocalcaemia in patients with metastatic bone disease treated with denosumab. European Journal of Cancer, 2015. 51(13): p. 1812-1821.
Ross AC, T.C., Yaktine AL, Del Valle HB (Eds), Dietary Reference Intakes for Calcium and Vitamin D. Institute of Medicine, Food and Nutrition Board, Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, 2011.
Van Poznak, C.H., et al., Association of osteonecrosis of the jaw with zoledronic acid treatment for bone metastases in patients with cancer. JAMA oncology, 2021. 7(2): p. 246-254.
Yarom, N., et al., Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. Journal of Clinical Oncology, 2019. 37(25): p. 2270-2290.
Cardoso, F., et al., ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). The Breast, 2014. 23(5): p. 489-502.
Van Poznak, C., et al., Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology–Cancer Care Ontario focused guideline update. Journal of Clinical Oncology, 2017. 35(35): p. 3978-3986.
Coleman, R., et al., Bone health in cancer: ESMO clinical practice guidelines. Annals of oncology, 2020. 31(12): p. 1650-1663.
Himelstein, A.L., et al., Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. Jama, 2017. 317(1): p. 48-58.
Amadori, D., et al., Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. The Lancet Oncology, 2013. 14(7): p. 663-670.
Hortobagyi, G.N., et al., Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA oncology, 2017. 3(7): p. 906-912.
Shapiro, C.L., et al., Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (Alliance). Journal of Clinical Oncology, 2017. 35(35): p. 3949-3955.
Clemons, M., et al., Two-year results of a randomised trial comparing 4-versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. Journal of Bone Oncology, 2021. 30: p. 100388.
Tu, M.M., et al., Cost-effectiveness analysis of 12-versus 4-weekly administration of bone-targeted agents in patients with bone metastases from breast and castration-resistant prostate cancer. Current Oncology, 2021. 28(3): p. 1847-1856.
Alzahrani, M., et al., Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers. Supportive Care in Cancer, 2022. 30(5): p. 3977-3984.
Clemons, M., et al., A randomised trial of 4-versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. European Journal of Cancer, 2021. 142: p. 132-140.
Rosen, L.S., et al., Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer journal (Sudbury, Mass.), 2001. 7(5): p. 377-387.
Palmieri, C., J.R. Fullarton, and J. Brown, Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. Clinical Cancer Research, 2013. 19(24): p. 6863-6872.
The treatment of metastatic carcinoma and myeloma of the femur. MSTS, ASTRO, ASCO Clinical practice guideline, December 02, 2020.
Anderson, K., et al., Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology, 2018. 36(8): p. 812-818.
Ross, J., et al., Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. Bmj, 2003. 327(7413): p. 469.
Mancini, I., J.-C. Dumon, and J.-J. Body, Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. Journal of clinical oncology, 2004. 22(17): p. 3587-3592.
